This drug reduces PD-L1 expression in mouse breast cancer cells and increases tumor cell production of T cell stimulants, such as CXCL10 and CXCL13 chemokines resulting in an increased lymphocyte recruitment within the TME [85,86,87]. The gene discussed is CD274; the disease is neoplasm.